Metastasis to the skeleton frequently occurs in breast carcinoma patients resulting in different skeletal-related events including pain, hypercalcemia, pathological fracture, and spinal cord or nerve root compression. Bisphosphonates are class of agents most frequently used to reduce skeletal-related events in patients with bone metastases by inhibiting osteoclast activity through inhibition of mevolanate pathway which is also important in cholesterol synthesis. Statins are cholesterol lowering agents and inhibit the same pathway. Therefore statins may also reduce skeletal-related events in breast cancer patients with bone metastases by inhibiting osteoclastic activity.

Acyl Coenzyme A↗

PubMed2006

Low bone mineral density value at the time of diagnosis of primary tumor in postmenopausal patients with operable breast cancer may increase bone metastasis risk.

Explore the source record for details and available documents.

Aged↗

PubMed2006

Albumin-bound paclitaxel, ABI-007 may show better efficacy than paclitaxel in basal-like breast cancers: association between caveolin-1 expression and ABI-007.

Explore the source record for details and available documents.

Albumin-Bound Paclitaxel↗

PubMed2006

Anterior tongue metastasis from lung cancer.

Explore the source record for details and available documents.

Carcinoma, Squamous Cell↗